Literature DB >> 25966853

Structure-activity relationships of the plasminogen modulator SMTP with respect to the inhibition of soluble epoxide hydrolase.

Naoki Matsumoto1, Eriko Suzuki1, Kota Tsujihara1, Yuuichi Nishimura1, Keiji Hasumi1,2.   

Abstract

A family of fungal metabolites, SMTP, is a small-molecule plasminogen modulator that enhances plasminogen activation, leading to thrombolysis. We recently demonstrated that SMTP-7 effectively treats ischemic stroke due to its thrombolytic activity as well as anti-inflammatory action, which is attributable to soluble epoxide hydrolase (sEH) inhibition. In this paper, we studied detailed structure-activity relationships of plasminogen modulation and sEH inhibition using 25 SMTP congeners including six newly synthesized ones. The results clearly demonstrate that the structure of the N-linked side chain of SMTP congeners markedly affect their activities toward plasminogen modulation and inhibitions of the two activities of sEH (C-terminal epoxide hydrolase and N-terminal phosphatase). A slight change in the N-linked side chain results in affording selectivity of SMTP congeners. Many congeners, which lacked plasminogen modulation activity, differently inhibited the two sEH activities depending on the structures of the N-linked side chain. Some congeners were active in plasminogen modulation and inhibition of both activities of sEH. These results help comprehensive understanding of ideal design of a drug useful for ischemic diseases that are associated with inflammation, such as stroke.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25966853     DOI: 10.1038/ja.2015.58

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  36 in total

1.  Pre-SMTP, a key precursor for the biosynthesis of the SMTP plasminogen modulators.

Authors:  Yuuichi Nishimura; Eriko Suzuki; Keiko Hasegawa; Naoko Nishimura; Yoshikazu Kitano; Keiji Hasumi
Journal:  J Antibiot (Tokyo)       Date:  2012-06-20       Impact factor: 2.649

Review 2.  Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems.

Authors:  Keiji Hasumi; Shingo Yamamichi; Tomotaka Harada
Journal:  FEBS J       Date:  2010-08-16       Impact factor: 5.542

3.  Enhancement of fibrin binding and activation of plasminogen by staplabin through induction of a conformational change in plasminogen.

Authors:  R Takayasu; K Hasumi; C Shinohara; A Endo
Journal:  FEBS Lett       Date:  1997-11-24       Impact factor: 4.124

4.  Mechanism of the action of SMTP-7, a novel small-molecule modulator of plasminogen activation.

Authors:  Keiji Koyanagi; Ritsuko Narasaki; Shingo Yamamichi; Eriko Suzuki; Keiji Hasumi
Journal:  Blood Coagul Fibrinolysis       Date:  2014-06       Impact factor: 1.276

5.  A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice.

Authors:  Keita Shibata; Terumasa Hashimoto; Koji Nobe; Keiji Hasumi; Kazuo Honda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-03       Impact factor: 3.000

6.  Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7.

Authors:  Terumasa Hashimoto; Keita Shibata; Hisayuki Ohata; Keiji Hasumi; Kazuo Honda
Journal:  J Pharmacol Sci       Date:  2014-05-01       Impact factor: 3.337

7.  Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain.

Authors:  Yosuke Akamatsu; Atsushi Saito; Miki Fujimura; Hiroaki Shimizu; Moataz Mekawy; Keiji Hasumi; Teiji Tominaga
Journal:  Neurosci Lett       Date:  2011-08-17       Impact factor: 3.046

8.  A new series of the SMTP plasminogen modulators with a phenylamine-based side chain.

Authors:  Haruki Koide; Keiko Hasegawa; Naoko Nishimura; Ritsuko Narasaki; Keiji Hasumi
Journal:  J Antibiot (Tokyo)       Date:  2012-04-18       Impact factor: 2.649

9.  Nonlysine-analog plasminogen modulators promote autoproteolytic generation of plasmin(ogen) fragments with angiostatin-like activity.

Authors:  Shigeki Ohyama; Tomotaka Harada; Toshihiro Chikanishi; Yutaka Miura; Keiji Hasumi
Journal:  Eur J Biochem       Date:  2004-02

10.  SMTP-7, a new thrombolytic agent, decreases hemorrhagic transformation after transient middle cerebral artery occlusion under warfarin anticoagulation in mice.

Authors:  Akira Ito; Kuniyasu Niizuma; Hiroaki Shimizu; Miki Fujimura; Keiji Hasumi; Teiji Tominaga
Journal:  Brain Res       Date:  2014-07-09       Impact factor: 3.252

View more
  5 in total

1.  SMTP-44D Exerts Antioxidant and Anti-Inflammatory Effects through Its Soluble Epoxide Hydrolase Inhibitory Action in Immortalized Mouse Schwann Cells upon High Glucose Treatment.

Authors:  Ryosuke Shinouchi; Keita Shibata; Shiori Jono; Keiji Hasumi; Koji Nobe
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

Review 2.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

3.  Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.

Authors:  Eriko Suzuki; Naoko Nishimura; Tetsuya Yoshikawa; Yudai Kunikiyo; Keiko Hasegawa; Keiji Hasumi
Journal:  Pharmacol Res Perspect       Date:  2018-12-05

Review 4.  Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.

Authors:  Keiji Hasumi; Eriko Suzuki
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

5.  Producing Novel Fibrinolytic Isoindolinone Derivatives in Marine Fungus Stachybotrys longispora FG216 by the Rational Supply of Amino Compounds According to Its Biosynthesis Pathway.

Authors:  Ying Yin; Qiang Fu; Wenhui Wu; Menghao Cai; Xiangshan Zhou; Yuanxing Zhang
Journal:  Mar Drugs       Date:  2017-07-05       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.